GlassScriptPhysician profile
Warren Reyes Ho
NPI 1073721965
$5,078.64
in general payments reported to CMS, 2019-2025
28 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $297 · 2021: $465 · 2022: $632 · 2023: $1,089 · 2024: $1,078 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Education: $50.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.33 |
| Education | $50.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $914.18 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $625.48 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $575.64 | 2022-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $458.93 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $453.89 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $451.33 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $278.97 | 2020-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $263.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $129.10 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $128.93 | 2023-2025 | Tarpeyo |
| Outset Medical INC | $128.64 | 2023-2024 | |
| Boston Scientific Corporation | $109.17 | 2024 | Freelink, Click |
| Akebia Therapeutics INC | $108.92 | 2020-2021 | |
| Horizon Therapeutics Plc | $66.61 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $56.72 | 2025 | Nxstage System One, Liberty Select Cycler, Velphoro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $54.85 | 2019-2025 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $45.07 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.47 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $24.75 | 2022 | |
| Recordati_rare_diseases_inc. | $24.54 | 2023 | Isturisa, Signifor Lar |
| Alnylam Pharmaceuticals INC. | $24.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.63 | 2020 | |
| Aurinia Pharma U.S., INC. | $15.95 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $15.55 | 2021 | |
| Ardelyx, INC. | $15.42 | 2024 | Ibsrela |
| Lilly USA, LLC | $15.17 | 2024 | Jardiance |
| Advanced Oxygen Therapy INC. | $10.05 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.